<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04133883</url>
  </required_header>
  <id_info>
    <org_study_id>Sobi.HAEM8-001</org_study_id>
    <nct_id>NCT04133883</nct_id>
  </id_info>
  <brief_title>Impact on French Physician's Haemophilia Treatment Management Decision Based on Systematic Joint Examination</brief_title>
  <acronym>A-MOVE</acronym>
  <official_title>A Study to Investigate if the Use of a Systematic Joint Examination (Ultrasound/Functional/Physical) Has an Impact on the Physician's Haemophilia Treatment Management Decision in Patients With Haemophilia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Orphan Biovitrum</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kantar Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Swedish Orphan Biovitrum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This low interventional study aims to describe if and how the haemophilia treatment
      management decisions are impacted by a systematic joint examination (ultrasound, functional,
      physical) in patients with haemophilia A in France.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will assess the behavior of the physicians with regards to haemophilia management
      decisions, and if systematic joint examination have an impact on their decisions. The main
      objective is to evaluate if the use of HEAD-US and Haemophilia Joint Health Score (HJHS) have
      an impact on these decisions. The study is classified as a low-interventional study due to
      mandated systematically assessment (HEAD-US, HJHS) on patients which may not be part of
      routine clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in haemophilia management based on systematic joint examinations of ankles, knees and elbows with HJHS and HEAD-US</measure>
    <time_frame>12 months</time_frame>
    <description>Yes/No</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Haemophilia A patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treated on-demand or prophylaxis with any Factor VIII (FVIII) product, plasma derived or recombinant (conventional or extended-half life) FVIII, according to routine clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasound, Haemophilia Joint Health Score</intervention_name>
    <description>Systematic joint examinations of ankles, knees and elbows</description>
    <arm_group_label>Haemophilia A patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 6-40 years

          -  Haemophilia A patients treated with plasma-derived factor VIII (pdFVIII) or
             recombinant (conventional or extended half-life) factor VIII (rFVIII)

          -  At least one joint bleeding episode prior to inclusion

          -  Signed informed consent

        Exclusion Criteria:

          -  Enrolment in another concurrent clinical interventional study, or intake of an
             Investigational Medicinal Product, within three months prior to inclusion in the study

          -  Presence of factor VIII antibodies (inhibitors) (≥0.60 Bethesda Unit [BU]/mL) at the
             latest available inhibitor test

          -  Joint surgery over the past year prior to inclusion in one of the following joints;
             left knee, right knee, left elbow, right elbow, left ankle and right ankle

          -  More than one joint replacement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Santagostino</last_name>
    <role>Study Director</role>
    <affiliation>Swedish Orphan Biovitrum</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sofia Bergenstråle</last_name>
    <phone>+46 8 697 2000</phone>
    <email>sofia.bergenstrale@sobi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Reserach site</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Reserach site</name>
      <address>
        <city>Chambéry</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Reserach site</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Reserach site</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Reserach site</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Reserach site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Reserach site</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Reserach site</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Reserach site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>joint health</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

